IT House reported on December 16 that ’s male contraceptive pill named YCT-529 entered Phase 1 clinical trials in the UK on December 13, which is an important development in the field of contraception.
The male birth control pill, created by YourChoice Therapeutics, is being tested in a Phase 1 clinical trial with 16 participants to test the pill's safety, tolerability and oral dose functionality.
IT Home Note: Over the past few decades, women have shouldered most of the birth control burden, from birth control pills to patches to intrauterine devices.
Male contraception mainly involves the use of condoms and vasectomy, but because vasectomy is irreversible, acceptance by men is low.
YCT-529's contraceptive mechanism relies primarily on retinoic acid receptor alpha (RAR-alpha), and it is precisely this protein that the researchers hope to induce long-lasting but reversible birth control through selective blockade of this protein while causing little effect elsewhere. Off-target effects (that is, they do not interact with targets other than those for which the drug was designed, that is, they do not produce side effects).
RAR-α locally blocks the production of vitamin A (which helps in the production and release of sperm). In existing animal studies, complete reversal has been observed 14 weeks after stopping use. Such a long buffer period also means missing a period. Two pills do not pose a high pregnancy risk.
